Cargando…

A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia

OBJECTIVE: Schizophrenia is a serious disease characterized by impairment in the perception or expression of reality, leading to occupational and social dysfunction. The use of antipsychotic medication is now universal in the first-line treatment of schizophrenia. This study was undertaken to compar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maitra, Arpita, Bhattacharyya, Swati, Mukhopadhyay, Sabyasachi, Mallick, Asim Kumar, Biswas, Supreeti, Singh, Om Prakash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609212/ https://www.ncbi.nlm.nih.gov/pubmed/33124591 http://dx.doi.org/10.9758/cpn.2020.18.4.587

Ejemplares similares

Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study
por: Matsuzaki, Haruna, et al.
Publicado: (2021)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2017)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Transdermal Asenapine in Schizophrenia: A Systematic Review
por: Carrithers, Brennan, et al.
Publicado: (2020)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
por: Boyda, Heidi N., et al.
Publicado: (2013)

Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine
por: Takao, Nagara, et al.
Publicado: (2021)

Asenapine for bipolar disorder
por: Scheidemantel, Thomas, et al.
Publicado: (2015)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
por: Bishara, Delia, et al.
Publicado: (2009)

Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report
por: Ochi, Shinichiro, et al.
Publicado: (2019)

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
por: Durgam, Suresh, et al.
Publicado: (2017)

The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
por: Thomas, Jennifer E., et al.
Publicado: (2015)

Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review
por: Stepanova, Ekaterina, et al.
Publicado: (2017)

Anthropometric parameters as indicators of metabolic derangements in schizophrenia patients stabilized on olanzapine in an Indian rural population
por: Rout, Jayanta Kumar, et al.
Publicado: (2012)

Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia
por: Ogyu, Kamiyu, et al.
Publicado: (2020)

Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
por: Cazorla, Pilar, et al.
Publicado: (2012)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder
por: Gonzalez, Jodi M, et al.
Publicado: (2011)

A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia
por: Singh, Om Prakash, et al.
Publicado: (2008)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study
por: Kinoshita, Toshihiko, et al.
Publicado: (2016)

M45. EFFICACY AND SAFETY OF THE ASENAPINE TRANSDERMAL PATCH, HP-3070 (SECUADO©), FOR SCHIZOPHRENIA: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, INPATIENT STUDY
Publicado: (2020)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

A Review of Asenapine in the Treatment of Bipolar Disorder
por: Vieta, Eduard, et al.
Publicado: (2017)

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
por: Stauffer, Virginia L, et al.
Publicado: (2010)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Asenapine effects in animal models of psychosis and cognitive function
por: Marston, Hugh M., et al.
Publicado: (2009)

Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
por: Lachaine, Jean, et al.
Publicado: (2014)

Asenapine augmentation in bipolar disorders: a case series
por: Marazziti, Donatella, et al.
Publicado: (2016)

Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070)
por: Suzuki, Katsumi, et al.
Publicado: (2021)

Treating Borderline personality disorder with Asenapine : Case report
por: Aboelenien, S. K. I. M., et al.
Publicado: (2023)

Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication
por: Kinoshita, Toshihiko, et al.
Publicado: (2023)

Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double–blind, multicentric trial
por: Shah, Sandip, et al.
Publicado: (2011)

Black hairy tongue with olanzapine: A rare case report
por: Kanodia, Shubhra, et al.
Publicado: (2017)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Teratogenicity with Olanzapine
por: Prakash, Sathya, et al.
Publicado: (2014)

Boosting the In Vivo Transdermal Bioavailability of Asenapine Maleate Using Novel Lavender Oil-Based Lipid Nanocapsules for Management of Schizophrenia
por: El-Tokhy, Fatma Sa’eed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tdadmp7hp3kt8rlsk3v6v64bts